Knockdown of Skp2 by siRNA inhibits melanoma cell growth in vitro and in vivo

Journal of Dermatological Science

Volumn 42, Issue 3, 2006, Pages 215-224

  Katagiri, Yoshiyuki ^a   Hozumi, Yutaka ^a   Kondo, Shigeo ^a  

^a YAMAGATA UNIVERSITY   (Japan)

Author keywords

In vivo; Melanoma; Sirna; Skp2; Ubiquitin

Indexed keywords

BENZYLOXYCARBONYLLEUCYL LEUCYL LEUCINE ALDEHYDE; BENZYLOXYCARBONYLLEUCYL-LEUCYL-LEUCINE ALDEHYDE; CYCLIN DEPENDENT KINASE INHIBITOR 1B; LEUPEPTIN; S PHASE KINASE ASSOCIATED PROTEIN; SMALL INTERFERING RNA;

ANIMAL; ARTICLE; CELL PROLIFERATION; DOWN REGULATION; DRUG EFFECT; EXPERIMENTAL MELANOMA; GENE EXPRESSION REGULATION; HUMAN; MELANOMA; METABOLISM; MOUSE; NUDE MOUSE; PATHOPHYSIOLOGY; RNA INTERFERENCE; TUMOR CELL LINE;

ANIMALS; CELL LINE, TUMOR; CELL PROLIFERATION; CYCLIN-DEPENDENT KINASE INHIBITOR P27; DOWN-REGULATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LEUPEPTINS; MELANOMA; MELANOMA, EXPERIMENTAL; MICE; MICE, NUDE; RNA INTERFERENCE; RNA, SMALL INTERFERING; S-PHASE KINASE-ASSOCIATED PROTEINS;

EID: 33745656961     PISSN: 09231811     EISSN: 1873569X     Source Type: Journal    
DOI: 10.1016/j.jdermsci.2005.12.016     Document Type: Article

References (42)

1. Sherr CJ, Roberts JM. CDK inhibitors: positive and negative regulators of G1-phase progression. Genes Dev 1994;9: 1149-63.
2. Morgan DO. Principles of CDK regulation. Nature 1995;374: 131-4.
3. Pagano M, Tam SW, Theodoras AM, Beer-Romero P, Del Sal G, Chau V, et al. Role of the ubiquitin-proteasome pathway in regulating abundance of the cyclin-dependent kinase inhibitor p27. Science 1995;269:682-5.
4. Shirane M, Harumiya Y, Ishida N, Hirai A, Miyamoto C, Hatakeyama S, et al. Down-regulation of p27(Kip1) by two mechanisms, ubiquitin-mediated degradation and proteolytic processing. J Biol Chem 1999;274:13886-93.
5. Hershko A. Roles of ubiquitin-mediated proteolysis in cell cycle control. Curr Opin Cell Biol 1997;9:788-99.
6. Bloom J, Pagano M. Deregulated degradation of the cdk inhibitor p27 and malignant transformation. Semin Cancer Biol 2003;13:41-7.
7. Hatakeyama S, Kitagawa M, Nakayama K, Shirane M, Matsumoto M, Hattori K, et al. Ubiquitin-dependent degradation of IkBa is mediated by a ubiquitin ligase Skp1/Cul1/F-box protein FWD1. Proc Natl Acad Sci USA 1999;96:3859-63.
8. Yaron A, Davis M, Lavon I, Amit S, Manning AM, Andersen JS, et al. Identification of the receptor component of the IkBβubiquitin ligase. Nature 1998;396:590-4.
9. Kitagawa M, Hatakeyama S, Shirane M, Matsumoto M, Ishida N, Hattori K, et al. An F-box protein FWD1 mediates ubiquitin-dependent ploteolysis of b-catenin. EMBO J 1999;18:2401-10.
10. Carrano AC, Eytan E, Hershko A, Pagano M. SKP2 is required for ubiquitin-mediated degradation of the CDK inhibitor p27. Nat Cell Biol 1999;1:193-9.
11. Koepp DM, Schaefer LK, Ye X, Keyomarsi K, Chu C, Harper JW, et al. Phosphorylation-dependent ubiquitination of cyclin E by the SCFFbw7 ubiquitin ligase. Science 2001;294:173-7.
12. Sutterluty H, Chatelain E, Mart A, et al. p45SKP2 promotes p27 degradation and induces S phase in quiescent cells. Nat Cell Biol 1999;1:207-14.
13. Tsvetkov LM, Yeh KH, Lee SJ, Sun H, Zhang H. p27(Kip1) ubiquitination and degradation is regulated by the SCF(Skp2) complex through phosphorylated Thr187 in p27. Curr Biol 1999;9:661-4.
14. Nakayama K, Nagahama H, Minamishima YA, Matsumoto M, Nakamichi I, Kitagawa K, et al. Targeted disruption of Skp2 results in accumulation of cyclin E and p27Kip1, polyploidy and centrosome overduplication. EMBO J 2000;19:2069-81.
15. von der Lehr N, Johansson S, Wu S, Bahram F, Castell A, Cetinkaya C, et al. The F-box protein Skp2 participates in c-Myc proteosomal degradation and acts as a cofactor for c-Myc-regulated transcription. Mol Cell 2003;11:1189-200.
16. Koepp DM, Schaefer LK, Ye X, Keyomarsi K, Chu C, Harper JW, et al. Phosphorylation-dependent ubiquitination of cyclin E by the SCFFbw7 ubiquitin ligase. Science 2001;294:173-7.
17. Yada M, Hatakeyama S, Kamura T, Nishiyama M, Tsunematsu R, Imaki H, et al. Phosphorylation-dependent degradation of c-Myc is mediated by the F-box protein Fbw7. EMBO J 2004;23:2116-25.
18. Mori K, Maeda Y, Kitaura H, Taira T, Iguchi-Ariga SM, Ariga H. MM-1, a novel c-Myc-associating protein that represses transcriptional activity of c-Myc. J Biol Chem 1998;273:29794- 800.
19. Loda M, Cukorm B, Tam SW, Lavin P, Fiorentino M, Draetta GF, et al. Increased proteasome-dependent degradation of the cyclin-dependent kinase inhibitor p27 in aggressive colorectal carcinomas. Nat Med 1997;3:231-4.
20. Catzavelos C, Bhattacharya N, Ung YC, Wilson JA, Roncari L, Sandhu C, et al. Decreased levels of the cell-cycle inhibitor p27Kip1 protein: prognostic implications in primary breast cancer. Nat Med 1997;3:227-30.
21. Mori M, Mimori K, Shiraishi T, Tanaka S, Ueo H, Sugimachi K, et al. p27 expression and gastric carcinoma. Nat Med 1997;3:593.
22. Kawana H, Tamaru J, Tanaka T, Hirai A, Saito Y, Kitagawa M, et al. Role of p27Kip1 and cyclin-dependent kinase 2 in the proliferation of non-small cell lung cancer. Am J Pathol 1998;153:505-13.
23. Kudo Y, Takata T, Ogawa I, Zhao M, Sato S, Takekoshi T, et al. Reduced expression of cyclin-dependent kinase inhibitor p27 is an indicator of malignant behavior of oral squamous cell carcinomas. Cancer 1998;83:2447-55.
24. Florenes VA, Maelandsmo GM, Kerbel RS, Slingerland JM, Nesland JM, Holm R. Protein expression of the cell-cycle inhibitor p27Kip1 in malignant melanoma: inverse correlation with disease-free survival. Am J Pathol 1998;153(1): 305-12.
25. Li Q, Murphy M, Ross J, Sheehan C, Carlson JA. Skp2 and p27kip1 expression in melanocytic nevi and melanoma: an inverse relationship. J Cutan Pathol 2004;31(10): 633-42.
26. Woenckhaus C, Maile S, Uffmann S, Bansemir M, Dittberner T, Poetsch M, et al. Expression of Skp2 and p27KIP1 in naevi and malignant melanoma of the skin and its relation to clinical outcome. Histol Histopathol 2005;20(2):501-8.
27. Hershko D, Bornstein G, Ben-Izhak O, Carrano A, Pagano M, Kranz MM, et al. Inverse relation between levels of p27Kip1 and of its ubiquitin ligase subunit SKp2 in colorectal carcinomas. Cancer 2001;91:1745-51.
28. Shapira M, Ben-Izhak O, Linn S, Futerman B, Minkov I, Hershko DD. The prognostic impact of the ubiquitin ligase subunits Skp2 and Cks1 in colorectal carcinoma. Cancer 2005;103(7):1336-46.
29. Gstaiger M, Jordan R, Lim M, Catzavelos C, Mestan J, Slingerland J, et al. Skp2 is oncogenic and overexpressed in human cancers. Proc Natl Acad Sci USA 2001;98:5043-8.
30. Kudo Y, Kitajima S, Sato S, Miyauchi M, Ogawa I, Takata T. High expression of S-phase kinase-interacting protein 2, human F-box protein, correlates with poor prognosis in oral squamous cell carcinomas. Cancer Res 2001;61: 7044-7.
31. Chiarle R, Fan Y, Piva R, Boggino H, Skolnik J, Novero D, et al. S-phase kinase-associated protein 2 expression in non-Hodgkin's lymphoma inversely correlates with p27 expression and defines cells in S phase. Am J Pathol 2002;160:1457-66.
32. Latres E, Chiarle R, Schulman B, et al. Role of the F-box protein Skp2 in lymphomagenesis. Proc Natl Acad Sci USA 2001;98:2515-20.
33. Signoretti S, Dimarcotullio L, Richardson A, et al. Oncogenic role of the ubiquitin ligase subunit Skp2 in human breast cancer. J Clin Invest 2002;110:633-41.
34. Yokoi S, Yasui K, Saito-Ohara F, et al. A novel target gene, SKP2, within the 5p13 amplicon that is frequently detected in small cell lung cancers. Am J Pathol 2002;161:207-16.
35. Masuda TA, Inoue H, Sonoda H, et al. Clinical and biological significance of S-phase kinase-associated protein 2 (Skp2) gene expression in gastric carcinoma: modulation of malignant phenotype by Skp2 overexpression, possibly via p27 proteolysis. Cancer Res 2000;62:3819-25.
36. Kondo S, Sato K, Sato N, Hozumi Y, Aso K. Establishment of cell lines from human malignant melanomas and their application to the assessment of natural killer-like cytotoxity. J Dermatol 1984;11(4):328-34.
37. Kudo Y, Kitajima S, Ogawa I, KitagawaM,MiyauchiM, Takata T. Small interfering RNA targeting of S phase kinase-interacting protein 2 inhibits cell growth of oral cancer cells by inhibiting p27 degradation. Mol Cancer Ther 2005;4(3):471-6.
38. Yokoi S, Yasui K, Iizasa T, Takahashi T, Fujisawa T, Inazawa J. Down-regulation of SKP2 induces apoptosis in lung-cancer cells. Cancer Sci 2003;94:344-9.
39. Yokoi S, Yasui K, Mori M, Iizasa T, Fujisawa T, Inazawa J. Amplification and overexpression of Skp2 are associatedwith metastasis of non-small-cell lung cancers to lymph nodes. Am J Pathol 2004;165:175-80.
40. Jiang F, Caraway NP, Li R, Katz RL. RNA silencing of S-phase kinase-interacting protein 2 inhibits proliferation and centrosome amplification in lung cancer cells. Oncogene 2005;24(21):3409-18.
41. Sumimoto H, Hirata K, Yamagata S, Miyoshi H, Miyagishi M, Taira K, et al. Effective inhibition of cell growth and invasion of melanoma by combined suppression of BRAF (V599E) and Skp2 with lentiviral RNAi. Int J Cancer 2006;118:472-6.
42. Toyoshima H, Hunter T. p27, a novel inhibitor of G1 cyclin-Cdk protein kinase activity, is related to p21. Cell 1994; 78:67-74.